Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.27M | 3.60M | 2.22M | 2.58M | 2.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.12M | 7.48M | 6.27M | 6.56M | 6.69M |
| Operating Income | -7.12M | -7.48M | -6.27M | -6.56M | -6.69M |
| Income Before Tax | -6.76M | -7.53M | -5.99M | -6.07M | -6.15M |
| Income Tax Expenses | 2.80K | 1.80K | -- | -5.00K | 5.00K |
| Earnings from Continuing Operations | -6.77M | -7.53M | -5.99M | -6.06M | -6.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.70K | 23.40K | 48.00K | 56.70K | 113.90K |
| Net Income | -6.76M | -7.51M | -5.94M | -6.01M | -6.04M |
| EBIT | -7.12M | -7.48M | -6.27M | -6.56M | -6.69M |
| EBITDA | -7.10M | -14.83M | -6.25M | -6.53M | -6.67M |
| EPS Basic | -0.21 | -0.43 | -0.17 | -0.17 | -0.21 |
| Normalized Basic EPS | -0.12 | -0.13 | -0.10 | -0.11 | -0.13 |
| EPS Diluted | -0.21 | -0.44 | -0.17 | -0.17 | -0.21 |
| Normalized Diluted EPS | -0.12 | -0.13 | -0.10 | -0.11 | -0.13 |
| Average Basic Shares Outstanding | 35.69M | 35.64M | 35.62M | 35.62M | 28.81M |
| Average Diluted Shares Outstanding | 35.69M | 35.64M | 35.62M | 35.62M | 28.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |